Clinical trial · no report yet · Phase 3
NCT00352846
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
- NCT00352846 ↗
- Completed
- M.D. Anderson Cancer Center
- 45 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 45 |
The trial
ClinicalTrials.gov- Official title
- Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Hodgkin's Lymphoma; Lymphoma
- Interventions
- Zoledronic Acid; Vitamin D; Calcium Carbonate
- Arms
- Vitamin D + Calcium Carbonate · Experimental
- Vitamin D + Calcium Carbonate + Zoledronic Acid · Experimental
- Enrollment
- 135
- Primary outcomes
- Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months
- Sponsor
- M.D. Anderson Cancer Center with Novartis
- Start
- Jan 2006
- Primary completion
- Sep 2011
- Results posted
- Yes
- Registry record
- NCT00352846 · updated Jul 2, 2013
Publications
linked from the registry- Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):99-105. doi: 10.1016/j.clml.2012.11.002. Epub 2012 Dec 29. PubMed 23276888